Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca: "Take some reassurance” from obesity drug bet
09:53am, Thursday, 09'th Nov 2023
AstraZeneca PLC (LSE:AZN) has upgraded its sales forecast for the year, in the hope that its foray into a semaglutide obesity drug will make up for concerns over its Covid-19 vaccine and bolster sales
AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines
05:05am, Thursday, 09'th Nov 2023
Anglo-Swedish drugmaker AstraZeneca on Thursday upped its earnings forecasts for the year as surging sales of cancer medicines offset plummeting sales of COVID vaccines.
AstraZeneca raises stakes in obesity drug race with Eccogene deal
03:50am, Thursday, 09'th Nov 2023
AstraZeneca moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China's Eccogene up to about $2 billion for an exclusive licence to develop an experim
AZ shares up 2% after it tweaks FY guidance higher
03:34am, Thursday, 09'th Nov 2023
Shares of AstraZeneca PLC (LSE:AZN) rose 2% following the upward revision to its full-year core earnings per share (EPS) and revenue forecasts. The Anglo-Swedish pharma giant now anticipates a low
AstraZeneca ups annual outlook on strong cancer drugs demand
02:06am, Thursday, 09'th Nov 2023
Drugmaker AstraZeneca raised its annual core profit outlook on Thursday, helped by strong demand for its oncology and rare blood disorder drugs.
9 Once-In-A Lifetime Blue-Chip Opportunities Yielding As Much As 10%
07:10am, Tuesday, 07'th Nov 2023
For weeks, I have pounded the table about the historic opportunity in REITs. The fundamentals were clear that now was the best time in 14 years to buy REITs. Last week, stocks ripped 6% higher, and RE
The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman – and Martin Shkreli
03:32pm, Monday, 06'th Nov 2023
Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades–the kind of drugs that should be cheap.
AstraZeneca results offer chance to set itself apart from rivals after FTSE 100 crown slips
12:26pm, Thursday, 02'nd Nov 2023
AstraZeneca PLC (LSE:AZN) approaches its third-quarter update with its shares having slipped 15% from the all-time highs reached in the spring, when it jostled back past Shell to regain top spot of t
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
10:34am, Thursday, 02'nd Nov 2023
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
AstraZeneca inks gene editing deal that could end up costing it $2.5bn
03:59am, Wednesday, 01'st Nov 2023
AstraZeneca PLC (LSE:AZN) has entered into a partnership and investment deal with French gene editing specialist biotech firm Cellectis (NASDAQ:CLLS) which it hopes will speed up the development of ne
AstraZeneca signs drug development deal with biotech Cellectis
03:17am, Wednesday, 01'st Nov 2023
AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to speed up the development of therapeutics in areas incl
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
07:32pm, Tuesday, 31'st Oct 2023
In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day.
Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?
10:33am, Monday, 30'th Oct 2023
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 No-Brainer Stocks to Buy for Under $100 Right Now
06:50am, Saturday, 28'th Oct 2023
AstraZeneca's slump presents a great buying opportunity. BioNTech's future prospects go well beyond COVID-19.
These healthcare stocks should come to life as boomers live their golden years
02:53pm, Wednesday, 25'th Oct 2023
Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healthcare.
